 Joshua Thurman
Concepts (607)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 41 | 2023 | 294 | 12.310 |
Why?
| | Complement Activation | 59 | 2023 | 350 | 11.710 |
Why?
| | Kidney Diseases | 23 | 2023 | 439 | 9.380 |
Why?
| | Complement Pathway, Alternative | 34 | 2022 | 117 | 7.110 |
Why?
| | Complement Factor H | 16 | 2022 | 61 | 5.620 |
Why?
| | Complement Inactivating Agents | 13 | 2023 | 43 | 5.230 |
Why?
| | Kidney | 31 | 2023 | 1353 | 4.660 |
Why?
| | Kidney Glomerulus | 15 | 2023 | 133 | 4.650 |
Why?
| | Reperfusion Injury | 15 | 2019 | 276 | 4.400 |
Why?
| | Complement Factor B | 25 | 2023 | 102 | 4.220 |
Why?
| | Glomerulonephritis | 9 | 2023 | 60 | 4.090 |
Why?
| | Complement C3 | 25 | 2023 | 192 | 3.230 |
Why?
| | Immunoglobulin M | 9 | 2023 | 253 | 3.210 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 39 | 2.800 |
Why?
| | Acute Kidney Injury | 12 | 2023 | 709 | 2.730 |
Why?
| | Autoimmune Diseases | 8 | 2023 | 398 | 2.660 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 6 | 2023 | 20 | 2.280 |
Why?
| | Receptors, Complement | 11 | 2022 | 115 | 1.870 |
Why?
| | Kidney Tubules | 7 | 2012 | 128 | 1.840 |
Why?
| | Lupus Nephritis | 7 | 2021 | 55 | 1.840 |
Why?
| | Graft Rejection | 9 | 2019 | 555 | 1.820 |
Why?
| | Receptor, Anaphylatoxin C5a | 6 | 2018 | 30 | 1.750 |
Why?
| | Nephrotic Syndrome | 2 | 2022 | 33 | 1.670 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 31 | 1.660 |
Why?
| | Antibodies | 3 | 2019 | 392 | 1.660 |
Why?
| | Mice | 72 | 2023 | 15520 | 1.550 |
Why?
| | Animals | 102 | 2023 | 33381 | 1.530 |
Why?
| | Complement C3b | 4 | 2023 | 30 | 1.510 |
Why?
| | Endothelial Cells | 5 | 2022 | 732 | 1.500 |
Why?
| | Epitopes | 8 | 2023 | 443 | 1.460 |
Why?
| | Inflammation | 15 | 2021 | 2566 | 1.450 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 681 | 1.380 |
Why?
| | Mice, Knockout | 33 | 2022 | 2680 | 1.320 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 39 | 1.300 |
Why?
| | Complement C3d | 8 | 2023 | 60 | 1.280 |
Why?
| | Epithelial Cells | 9 | 2022 | 963 | 1.280 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 16 | 1.220 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1284 | 1.180 |
Why?
| | Contrast Media | 4 | 2018 | 373 | 1.160 |
Why?
| | Mice, Inbred C57BL | 42 | 2022 | 4908 | 1.150 |
Why?
| | Glomerulonephritis, Membranoproliferative | 3 | 2023 | 14 | 1.120 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 19 | 1.090 |
Why?
| | Complement C5a | 6 | 2018 | 60 | 1.060 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 62 | 1.060 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 18 | 1.050 |
Why?
| | Organ Transplantation | 2 | 2019 | 165 | 1.040 |
Why?
| | Humans | 95 | 2023 | 118972 | 1.030 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 410 | 1.010 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 907 | 0.900 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 90 | 0.890 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 227 | 0.890 |
Why?
| | Nephritis | 2 | 2013 | 30 | 0.890 |
Why?
| | Kidney Transplantation | 8 | 2019 | 585 | 0.870 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 24 | 0.860 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3174 | 0.830 |
Why?
| | Disease Models, Animal | 29 | 2021 | 3730 | 0.820 |
Why?
| | Complement Membrane Attack Complex | 6 | 2018 | 35 | 0.810 |
Why?
| | Biomarkers | 15 | 2023 | 3588 | 0.790 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 18 | 0.790 |
Why?
| | Cardiolipins | 1 | 2021 | 73 | 0.780 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 356 | 0.770 |
Why?
| | Cyclosporine | 3 | 2019 | 173 | 0.720 |
Why?
| | Otitis Media | 5 | 2016 | 146 | 0.710 |
Why?
| | Immunoglobulin G | 11 | 2023 | 788 | 0.700 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 5 | 0.690 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 60 | 0.680 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 667 | 0.670 |
Why?
| | Vascular System Injuries | 1 | 2019 | 70 | 0.670 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 227 | 0.660 |
Why?
| | Kidney Failure, Chronic | 3 | 2021 | 516 | 0.660 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.650 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 96 | 0.640 |
Why?
| | Autoantibodies | 10 | 2023 | 1335 | 0.630 |
Why?
| | Doxorubicin | 4 | 2023 | 302 | 0.630 |
Why?
| | Glomerulonephritis, IGA | 1 | 2017 | 11 | 0.630 |
Why?
| | B-Lymphocytes | 7 | 2022 | 770 | 0.600 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 401 | 0.600 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 49 | 0.600 |
Why?
| | Transplantation, Homologous | 3 | 2019 | 415 | 0.590 |
Why?
| | Annexin A2 | 1 | 2016 | 10 | 0.560 |
Why?
| | Liver Neoplasms | 1 | 2020 | 527 | 0.560 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 82 | 0.560 |
Why?
| | Renal Insufficiency | 1 | 2018 | 150 | 0.550 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 141 | 0.540 |
Why?
| | Peptide Fragments | 1 | 2019 | 702 | 0.520 |
Why?
| | Pregnancy Complications | 3 | 2018 | 448 | 0.510 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1206 | 0.510 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1167 | 0.510 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 28 | 0.500 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 461 | 0.500 |
Why?
| | Male | 46 | 2022 | 57801 | 0.480 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 9 | 0.450 |
Why?
| | Female | 42 | 2023 | 61564 | 0.450 |
Why?
| | Complement C3a | 3 | 2014 | 33 | 0.440 |
Why?
| | Liver | 2 | 2020 | 1816 | 0.430 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 82 | 0.430 |
Why?
| | Nanoparticles | 2 | 2013 | 325 | 0.430 |
Why?
| | Immunity, Humoral | 1 | 2013 | 117 | 0.430 |
Why?
| | Autoimmunity | 5 | 2022 | 831 | 0.420 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 260 | 0.420 |
Why?
| | Molecular Imaging | 1 | 2012 | 54 | 0.420 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 589 | 0.410 |
Why?
| | Complement C1q | 3 | 2014 | 38 | 0.410 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 127 | 0.410 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 827 | 0.410 |
Why?
| | Complement C2 | 2 | 2011 | 6 | 0.400 |
Why?
| | CD55 Antigens | 3 | 2020 | 26 | 0.370 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 26 | 0.370 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 66 | 0.370 |
Why?
| | Blotting, Western | 7 | 2016 | 1194 | 0.360 |
Why?
| | Oxidative Stress | 7 | 2019 | 1178 | 0.360 |
Why?
| | Cell Membrane | 4 | 2022 | 710 | 0.360 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 34 | 0.360 |
Why?
| | Disease Susceptibility | 2 | 2020 | 331 | 0.350 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 330 | 0.350 |
Why?
| | Protozoan Proteins | 3 | 1998 | 67 | 0.350 |
Why?
| | Properdin | 2 | 2020 | 8 | 0.340 |
Why?
| | Cytokines | 5 | 2019 | 1900 | 0.330 |
Why?
| | Antibody Specificity | 2 | 2021 | 184 | 0.330 |
Why?
| | Diarrhea | 1 | 2009 | 181 | 0.330 |
Why?
| | Signal Transduction | 9 | 2020 | 4709 | 0.320 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.320 |
Why?
| | Complement C4 | 5 | 2021 | 26 | 0.320 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 129 | 0.320 |
Why?
| | Adult | 13 | 2023 | 31512 | 0.310 |
Why?
| | Uremia | 2 | 2021 | 18 | 0.310 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 62 | 0.310 |
Why?
| | Graft Survival | 4 | 2019 | 504 | 0.310 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.310 |
Why?
| | Phagocytosis | 4 | 2023 | 364 | 0.300 |
Why?
| | Metabolomics | 4 | 2019 | 550 | 0.300 |
Why?
| | Podocytes | 2 | 2020 | 57 | 0.300 |
Why?
| | Chemokines, CXC | 1 | 2007 | 64 | 0.300 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 131 | 0.290 |
Why?
| | Adaptive Immunity | 2 | 2019 | 161 | 0.290 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 114 | 0.290 |
Why?
| | Flow Cytometry | 4 | 2022 | 1085 | 0.290 |
Why?
| | Pilot Projects | 3 | 2021 | 1419 | 0.280 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 203 | 0.280 |
Why?
| | Cells, Cultured | 6 | 2019 | 4077 | 0.280 |
Why?
| | Protein Binding | 6 | 2019 | 1975 | 0.280 |
Why?
| | Immune System Diseases | 1 | 2006 | 35 | 0.270 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1691 | 0.270 |
Why?
| | Chemokines | 1 | 2007 | 230 | 0.270 |
Why?
| | Organ Specificity | 3 | 2020 | 278 | 0.270 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 421 | 0.260 |
Why?
| | NF-kappa B | 3 | 2016 | 670 | 0.260 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 25 | 0.260 |
Why?
| | Cell Line | 6 | 2017 | 2707 | 0.260 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 22 | 0.260 |
Why?
| | Fetal Death | 1 | 2005 | 52 | 0.260 |
Why?
| | Biopsy | 3 | 2019 | 1079 | 0.260 |
Why?
| | Caspases | 1 | 2006 | 269 | 0.250 |
Why?
| | Child | 11 | 2023 | 19129 | 0.250 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 19 | 0.250 |
Why?
| | Macular Degeneration | 3 | 2012 | 151 | 0.240 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 355 | 0.240 |
Why?
| | Immunity, Innate | 6 | 2017 | 745 | 0.240 |
Why?
| | Disease Progression | 4 | 2017 | 2490 | 0.240 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 28 | 0.240 |
Why?
| | Middle Aged | 10 | 2022 | 27617 | 0.230 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 10 | 0.230 |
Why?
| | Rats | 8 | 2021 | 5392 | 0.230 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 39 | 0.230 |
Why?
| | Prognosis | 5 | 2022 | 3443 | 0.230 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 84 | 0.220 |
Why?
| | Tacrolimus | 2 | 2014 | 151 | 0.220 |
Why?
| | Ischemia | 3 | 2015 | 374 | 0.220 |
Why?
| | Case-Control Studies | 2 | 2021 | 3171 | 0.220 |
Why?
| | Proteomics | 4 | 2018 | 876 | 0.220 |
Why?
| | Allografts | 2 | 2019 | 135 | 0.210 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 195 | 0.210 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 65 | 0.210 |
Why?
| | CD59 Antigens | 3 | 2011 | 21 | 0.210 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 19 | 0.200 |
Why?
| | Glutamic Acid | 1 | 2023 | 224 | 0.200 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 19 | 0.200 |
Why?
| | Myoglobin | 1 | 2021 | 15 | 0.200 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 76 | 0.200 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 408 | 0.200 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 44 | 0.200 |
Why?
| | Immune System | 1 | 2022 | 181 | 0.200 |
Why?
| | Paraffin Embedding | 1 | 2021 | 22 | 0.200 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 31 | 0.200 |
Why?
| | Formaldehyde | 1 | 2021 | 50 | 0.200 |
Why?
| | Proteinuria | 3 | 2012 | 99 | 0.200 |
Why?
| | Frozen Sections | 1 | 2021 | 24 | 0.190 |
Why?
| | Apoptosis | 2 | 2011 | 2484 | 0.190 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 22 | 0.190 |
Why?
| | Aged | 7 | 2021 | 19657 | 0.190 |
Why?
| | Albuminuria | 2 | 2015 | 195 | 0.190 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 19 | 0.190 |
Why?
| | Staining and Labeling | 1 | 2021 | 146 | 0.190 |
Why?
| | Dendritic Cells | 2 | 2022 | 442 | 0.190 |
Why?
| | Treatment Outcome | 3 | 2021 | 9342 | 0.180 |
Why?
| | Up-Regulation | 3 | 2019 | 872 | 0.180 |
Why?
| | Critical Illness | 2 | 2023 | 662 | 0.180 |
Why?
| | T-Lymphocytes | 5 | 2022 | 1774 | 0.180 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 10 | 0.180 |
Why?
| | Urinalysis | 1 | 2019 | 68 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 527 | 0.170 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 194 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 167 | 0.170 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 130 | 0.170 |
Why?
| | Sepsis | 2 | 2016 | 531 | 0.170 |
Why?
| | Complement C4a | 1 | 2018 | 7 | 0.170 |
Why?
| | North America | 1 | 2019 | 266 | 0.170 |
Why?
| | Complement C5 | 3 | 2020 | 75 | 0.160 |
Why?
| | Vascular Remodeling | 1 | 2020 | 152 | 0.160 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2674 | 0.160 |
Why?
| | Granulocytes | 2 | 2016 | 79 | 0.160 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 17 | 0.160 |
Why?
| | Lung | 5 | 2019 | 3664 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 982 | 0.160 |
Why?
| | HLA Antigens | 1 | 2019 | 230 | 0.160 |
Why?
| | Erythrocytes | 2 | 2020 | 641 | 0.160 |
Why?
| | Adolescent | 7 | 2021 | 18480 | 0.160 |
Why?
| | Organelles | 1 | 1998 | 55 | 0.160 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 37 | 0.150 |
Why?
| | Cyclophilins | 1 | 2017 | 29 | 0.150 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 26 | 0.150 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 683 | 0.150 |
Why?
| | Brain Injuries | 3 | 2007 | 484 | 0.150 |
Why?
| | Gene Expression | 6 | 2017 | 1489 | 0.150 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 9 | 0.150 |
Why?
| | Brachial Artery | 1 | 2018 | 181 | 0.150 |
Why?
| | Cell Differentiation | 2 | 2022 | 1753 | 0.150 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.150 |
Why?
| | Interferon-beta | 2 | 2007 | 82 | 0.140 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 870 | 0.140 |
Why?
| | Bleomycin | 1 | 2018 | 228 | 0.140 |
Why?
| | Macrophages | 3 | 2013 | 1324 | 0.140 |
Why?
| | Cell Aggregation | 1 | 2016 | 24 | 0.140 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 60 | 0.140 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 133 | 0.140 |
Why?
| | Phenols | 1 | 2017 | 85 | 0.140 |
Why?
| | Tuberculosis | 1 | 2019 | 240 | 0.140 |
Why?
| | Prospective Studies | 4 | 2023 | 6471 | 0.140 |
Why?
| | Collagen Type VII | 3 | 2018 | 13 | 0.140 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 266 | 0.140 |
Why?
| | Mucin-5B | 1 | 2018 | 175 | 0.140 |
Why?
| | Blood Pressure | 1 | 2003 | 1664 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 969 | 0.140 |
Why?
| | Ear, Middle | 3 | 2012 | 92 | 0.140 |
Why?
| | Complement C5b | 1 | 2015 | 4 | 0.140 |
Why?
| | Carboxypeptidases | 1 | 2015 | 14 | 0.140 |
Why?
| | MicroRNAs | 1 | 2022 | 637 | 0.130 |
Why?
| | Interferon-alpha | 2 | 2007 | 191 | 0.130 |
Why?
| | Immunoprecipitation | 1 | 2016 | 161 | 0.130 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 5 | 0.130 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 8 | 0.130 |
Why?
| | Inflammation Mediators | 3 | 2019 | 502 | 0.130 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 52 | 0.130 |
Why?
| | Vaccinia virus | 1 | 2015 | 34 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 102 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 420 | 0.130 |
Why?
| | Fibroblasts | 1 | 2020 | 842 | 0.130 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 5 | 0.130 |
Why?
| | Vasodilation | 1 | 2018 | 457 | 0.130 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 136 | 0.130 |
Why?
| | Analysis of Variance | 2 | 2010 | 1293 | 0.130 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 94 | 0.120 |
Why?
| | Eustachian Tube | 1 | 2014 | 4 | 0.120 |
Why?
| | Ultrasonography | 1 | 2018 | 716 | 0.120 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.120 |
Why?
| | Mast Cells | 1 | 2015 | 115 | 0.120 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1308 | 0.120 |
Why?
| | Edema | 1 | 2015 | 124 | 0.120 |
Why?
| | Hypertension | 1 | 2003 | 1203 | 0.120 |
Why?
| | Mesangial Cells | 1 | 2013 | 2 | 0.120 |
Why?
| | Immunoglobulins | 2 | 2020 | 154 | 0.120 |
Why?
| | Models, Immunological | 2 | 2012 | 94 | 0.120 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 53 | 0.120 |
Why?
| | Neutrophils | 2 | 2013 | 1233 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 79 | 0.120 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.120 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 294 | 0.120 |
Why?
| | Cricetulus | 2 | 2010 | 98 | 0.120 |
Why?
| | CHO Cells | 2 | 2010 | 143 | 0.110 |
Why?
| | Recurrence | 1 | 2016 | 975 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 396 | 0.110 |
Why?
| | Cricetinae | 2 | 2010 | 262 | 0.110 |
Why?
| | Blood Platelets | 1 | 2016 | 369 | 0.110 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 85 | 0.110 |
Why?
| | Acute Disease | 3 | 2014 | 940 | 0.110 |
Why?
| | Serum | 1 | 2013 | 63 | 0.110 |
Why?
| | Genetic Variation | 1 | 2018 | 926 | 0.110 |
Why?
| | Pregnancy | 4 | 2018 | 5690 | 0.110 |
Why?
| | Sirolimus | 1 | 2014 | 195 | 0.110 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1067 | 0.110 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 119 | 0.110 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 50 | 0.110 |
Why?
| | Genotype | 1 | 2018 | 1882 | 0.110 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 176 | 0.110 |
Why?
| | Amino Acids | 1 | 2016 | 464 | 0.110 |
Why?
| | Skin | 2 | 2015 | 657 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2016 | 681 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2013 | 187 | 0.110 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 359 | 0.110 |
Why?
| | Rhadinovirus | 1 | 2012 | 16 | 0.110 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 49 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 451 | 0.110 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 381 | 0.110 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 41 | 0.110 |
Why?
| | Rituximab | 1 | 2013 | 155 | 0.100 |
Why?
| | Acute Lung Injury | 1 | 2015 | 310 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 653 | 0.100 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 472 | 0.100 |
Why?
| | Mitochondria | 1 | 2017 | 786 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2015 | 749 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 984 | 0.100 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 95 | 0.100 |
Why?
| | Extracellular Fluid | 1 | 2011 | 32 | 0.100 |
Why?
| | Spleen | 1 | 2013 | 510 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2017 | 812 | 0.100 |
Why?
| | Plasma Exchange | 1 | 2010 | 21 | 0.100 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 142 | 0.100 |
Why?
| | Tissue Distribution | 3 | 2019 | 334 | 0.100 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 124 | 0.090 |
Why?
| | Blister | 2 | 2008 | 39 | 0.090 |
Why?
| | Down-Regulation | 4 | 2020 | 627 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1384 | 0.090 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 12 | 0.090 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 37 | 0.090 |
Why?
| | Opsonin Proteins | 1 | 2010 | 26 | 0.090 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 120 | 0.090 |
Why?
| | Dextrans | 1 | 2010 | 74 | 0.090 |
Why?
| | Collagen Type II | 1 | 2009 | 48 | 0.090 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 300 | 0.090 |
Why?
| | Microbial Viability | 1 | 2010 | 81 | 0.090 |
Why?
| | Osteoarthritis | 1 | 2011 | 176 | 0.090 |
Why?
| | Time Factors | 4 | 2015 | 6412 | 0.090 |
Why?
| | Antibody Formation | 1 | 2010 | 276 | 0.090 |
Why?
| | Cell Hypoxia | 1 | 2010 | 220 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2436 | 0.080 |
Why?
| | RNA, Messenger | 6 | 2022 | 2657 | 0.080 |
Why?
| | Image Enhancement | 1 | 2010 | 181 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 412 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1794 | 0.080 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.080 |
Why?
| | Liver Regeneration | 1 | 2008 | 34 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2017 | 1180 | 0.080 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 14 | 0.080 |
Why?
| | Allergens | 1 | 2011 | 424 | 0.080 |
Why?
| | Young Adult | 2 | 2021 | 10793 | 0.080 |
Why?
| | Hemolysis | 2 | 2020 | 174 | 0.080 |
Why?
| | Bacteremia | 1 | 2010 | 161 | 0.080 |
Why?
| | Neurons | 2 | 2006 | 1345 | 0.080 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 22 | 0.080 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 66 | 0.080 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 44 | 0.080 |
Why?
| | Binding Sites | 3 | 2016 | 1224 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1597 | 0.070 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 69 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 159 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2275 | 0.070 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 164 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 2017 | 546 | 0.070 |
Why?
| | Poly I-C | 1 | 2006 | 55 | 0.070 |
Why?
| | Immunization, Passive | 1 | 2006 | 81 | 0.070 |
Why?
| | Leukocytes | 1 | 2008 | 290 | 0.070 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 65 | 0.070 |
Why?
| | Renal Circulation | 1 | 2006 | 75 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2009 | 378 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 709 | 0.070 |
Why?
| | Antigens, Surface | 1 | 2006 | 156 | 0.070 |
Why?
| | Complement C6 | 2 | 2018 | 9 | 0.070 |
Why?
| | Nephrectomy | 1 | 2006 | 162 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2025 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 490 | 0.070 |
Why?
| | Mutation | 1 | 2016 | 3457 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2007 | 263 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2478 | 0.070 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 136 | 0.070 |
Why?
| | Basement Membrane | 1 | 2005 | 32 | 0.070 |
Why?
| | Placental Insufficiency | 1 | 2006 | 104 | 0.070 |
Why?
| | Random Allocation | 1 | 2006 | 344 | 0.060 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 111 | 0.060 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 18 | 0.060 |
Why?
| | Probability | 1 | 2006 | 305 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 892 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2005 | 49 | 0.060 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 303 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2220 | 0.060 |
Why?
| | Brain | 2 | 2006 | 2490 | 0.060 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 167 | 0.060 |
Why?
| | Lung Injury | 1 | 2006 | 210 | 0.060 |
Why?
| | Age Factors | 1 | 2011 | 2995 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1055 | 0.060 |
Why?
| | Collagen | 1 | 2006 | 433 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 367 | 0.060 |
Why?
| | Compulsive Behavior | 1 | 2003 | 6 | 0.060 |
Why?
| | Drinking Behavior | 1 | 2003 | 11 | 0.060 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 29 | 0.060 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 22 | 0.060 |
Why?
| | Annexins | 1 | 2023 | 3 | 0.060 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.060 |
Why?
| | Myocardium | 1 | 2009 | 970 | 0.060 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.060 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.060 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 44 | 0.060 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 59 | 0.060 |
Why?
| | Energy Metabolism | 2 | 2019 | 767 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 363 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 204 | 0.060 |
Why?
| | Hypothyroidism | 1 | 2003 | 68 | 0.050 |
Why?
| | Methionine | 1 | 2023 | 145 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 200 | 0.050 |
Why?
| | Cartilage, Articular | 1 | 2006 | 306 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2062 | 0.050 |
Why?
| | Neutralization Tests | 2 | 2015 | 66 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2003 | 726 | 0.050 |
Why?
| | HLA-D Antigens | 1 | 2022 | 36 | 0.050 |
Why?
| | Ubiquitination | 1 | 2022 | 87 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 250 | 0.050 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 64 | 0.050 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 468 | 0.050 |
Why?
| | Phospholipase D | 1 | 2020 | 7 | 0.050 |
Why?
| | Cholecalciferol | 1 | 2021 | 51 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2022 | 194 | 0.050 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 148 | 0.050 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 32 | 0.050 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 136 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2071 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 355 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2003 | 965 | 0.050 |
Why?
| | Particle Size | 1 | 2021 | 345 | 0.050 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 576 | 0.050 |
Why?
| | Child, Preschool | 2 | 2015 | 9491 | 0.050 |
Why?
| | Cell Movement | 2 | 2015 | 896 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 95 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 100 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 31 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 23 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 143 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 75 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 2851 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 613 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 211 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 307 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.040 |
Why?
| | Brefeldin A | 1 | 1998 | 14 | 0.040 |
Why?
| | Cyclopentanes | 1 | 1998 | 16 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1998 | 53 | 0.040 |
Why?
| | A549 Cells | 1 | 2018 | 48 | 0.040 |
Why?
| | Immunity, Active | 1 | 1998 | 10 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 311 | 0.040 |
Why?
| | Aotidae | 1 | 1998 | 7 | 0.040 |
Why?
| | Parasitemia | 1 | 1998 | 9 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 47 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 27 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 379 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 405 | 0.040 |
Why?
| | Macrolides | 1 | 1998 | 57 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 567 | 0.040 |
Why?
| | Vitamin D | 1 | 2021 | 354 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 75 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 635 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 372 | 0.040 |
Why?
| | Germinal Center | 1 | 2017 | 47 | 0.040 |
Why?
| | Immunomodulation | 1 | 2017 | 89 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 154 | 0.040 |
Why?
| | Recombination, Genetic | 1 | 1998 | 173 | 0.040 |
Why?
| | DNA Damage | 1 | 2019 | 357 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 173 | 0.040 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 95 | 0.040 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 12 | 0.040 |
Why?
| | Biological Transport, Active | 1 | 2016 | 73 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1171 | 0.040 |
Why?
| | Infant | 1 | 2009 | 8293 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 9 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 13 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 181 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 98 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 123 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 155 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 310 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 33 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 23 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 53 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 25 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 69 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 208 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 690 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 740 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 226 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 503 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 215 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 245 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 5 | 0.030 |
Why?
| | Pyridones | 1 | 2015 | 119 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 37 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 1781 | 0.030 |
Why?
| | Water Deprivation | 2 | 2003 | 9 | 0.030 |
Why?
| | Hypoxia | 1 | 2020 | 963 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1158 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 583 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 280 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 339 | 0.030 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 95 | 0.030 |
Why?
| | International Cooperation | 1 | 2013 | 177 | 0.030 |
Why?
| | Coinfection | 1 | 2014 | 119 | 0.030 |
Why?
| | Complement C4b-Binding Protein | 1 | 2012 | 3 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2871 | 0.030 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.030 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 106 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 140 | 0.030 |
Why?
| | Gluconeogenesis | 1 | 2012 | 66 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 361 | 0.030 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 79 | 0.030 |
Why?
| | Glucose | 1 | 2017 | 953 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 306 | 0.030 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 25 | 0.030 |
Why?
| | Synovial Fluid | 1 | 2011 | 56 | 0.030 |
Why?
| | Phosphates | 1 | 2012 | 167 | 0.030 |
Why?
| | Ovalbumin | 1 | 2011 | 165 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2012 | 399 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 356 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2015 | 542 | 0.030 |
Why?
| | Glycolysis | 1 | 2012 | 224 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 155 | 0.020 |
Why?
| | Joints | 1 | 2011 | 85 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 160 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 408 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 327 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 271 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 100 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 508 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 129 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 305 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 183 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 276 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 206 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 434 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1267 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 422 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 213 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 291 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1868 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1510 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 397 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1012 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 23 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 46 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 823 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1094 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 156 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 86 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 21 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 69 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 832 | 0.020 |
Why?
| | Biomedical Research | 1 | 2013 | 612 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 155 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 344 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 47 | 0.020 |
Why?
| | Vaccination | 1 | 2015 | 1222 | 0.020 |
Why?
| | Cattle | 1 | 2009 | 978 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 14 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 770 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 55 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 48 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 67 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 412 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2159 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4552 | 0.020 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 55 | 0.020 |
Why?
| | Synovial Membrane | 1 | 2006 | 71 | 0.020 |
Why?
| | fas Receptor | 1 | 2006 | 98 | 0.020 |
Why?
| | Trachea | 1 | 2007 | 226 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 220 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 127 | 0.020 |
Why?
| | Models, Molecular | 1 | 2010 | 1435 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2012 | 2874 | 0.020 |
Why?
| | Cell Death | 1 | 2006 | 339 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2006 | 306 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 3003 | 0.020 |
Why?
| | Swine | 1 | 2006 | 730 | 0.020 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 25 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 513 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 290 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 879 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 5 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 32 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 688 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 185 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 486 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1047 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 87 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1715 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1945 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2445 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 968 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2179 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 446 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 638 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 2158 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 22 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 109 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 362 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|